Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00931073 · ClinicalTrials.gov registry record · Phase 1
A Phase I Study To Estimate The Effect Of Ketoconazole And Omeprazole On The Pharmacokinetics Of Dimebon In Healthy Subjects Who Are Normal Or Poor CYP2D6 Metabolizers
A Phase 1 study, sponsored by Pfizer.
- Completed
- Registry status
- Phase 1
- Development phase
- 24
- Enrollment target
NCT00931073 is a Phase 1 study that has completed, run by Pfizer. The registered enrollment target is 24 participants.
The verdict
NCT00931073, a Phase 1 study, has completed, sponsored by Pfizer.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 24 participants
- Enrollment target
Study Summary
This study will evaluate the potential for a drug-drug interaction of Dimebon with ketoconazole and omeprazole, potent inhibitors of the drug metabolizing enzymes CYP3A4 and CYP2C19, respectively.
Interventions
- DRUG Dimebon alone
- DRUG Dimebon + Ketoconazole
- DRUG Dimebon + Omeprazole
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 24 participants |
| Start Date | 2009-07 |
| Est. Completion | 2009-10 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00931073
The ClinicalTrials.gov registry entry for NCT00931073 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 24 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pfizer, which has 1,845 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Dimebon alone is the first listed.
NCT00931073 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00931073 about?
NCT00931073 is a clinical study titled "A Phase I Study To Estimate The Effect Of Ketoconazole And Omeprazole On The Pharmacokinetics Of Dimebon In Healthy Subjects Who Are Normal Or Poor CYP2D6 Metabolizers". This study will evaluate the potential for a drug-drug interaction of Dimebon with ketoconazole and omeprazole, potent inhibitors of the drug metabolizing enzymes CYP3A4 and CYP2C19, respectively.
What is the current status of trial NCT00931073?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 24 participants. The study started on 2009-07. Estimated completion is 2009-10.
What interventions are being tested in trial NCT00931073?
The interventions under investigation include: Dimebon alone (DRUG), Dimebon + Ketoconazole (DRUG), Dimebon + Omeprazole (DRUG).
Who is sponsoring clinical trial NCT00931073?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.